BGXX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. BGXX has a bad profitability rating. Also its financial health evaluation is rather negative. BGXX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

BGXX had negative earnings in the past year.
In the past year BGXX has reported a negative cash flow from operations.
BGXX had negative earnings in each of the past 5 years.
BGXX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of BGXX (-62.04%) is worse than 70.26% of its industry peers.
With a Return On Equity value of -100.53%, BGXX perfoms like the industry average, outperforming 40.51% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-62.04%
ROE	-100.53%
ROIC	N/A

ROA(3y)-75.05%

ROA(5y)-54.76%

ROE(3y)-129.62%

ROE(5y)-88.27%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BGXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, BGXX has more shares outstanding
Compared to 1 year ago, BGXX has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that BGXX is in the distress zone and has some risk of bankruptcy.
BGXX's Altman-Z score of -3.41 is in line compared to the rest of the industry. BGXX outperforms 42.56% of its industry peers.
BGXX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.05, BGXX perfoms like the industry average, outperforming 51.28% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	-3.41

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.02 indicates that BGXX may have some problems paying its short term obligations.
The Current ratio of BGXX (0.02) is worse than 99.49% of its industry peers.
BGXX has a Quick Ratio of 0.02. This is a bad value and indicates that BGXX is not financially healthy enough and could expect problems in meeting its short term obligations.
BGXX has a Quick ratio of 0.02. This is amonst the worse of the industry: BGXX underperforms 99.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.02
Quick Ratio	0.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.28% over the past year.

EPS 1Y (TTM)40.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%62.05%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.